Azole resistance in Aspergillus fumigatus- comprehensive review.
Aspergillus fumigatus
Aspergillosis
Azole
Drug resistance
Ergosterol
Infection
Journal
Archives of microbiology
ISSN: 1432-072X
Titre abrégé: Arch Microbiol
Pays: Germany
ID NLM: 0410427
Informations de publication
Date de publication:
15 Jun 2024
15 Jun 2024
Historique:
received:
02
05
2024
accepted:
31
05
2024
revised:
28
05
2024
medline:
15
6
2024
pubmed:
15
6
2024
entrez:
15
6
2024
Statut:
epublish
Résumé
Aspergillus fumigatus is a ubiquitous filamentous fungus commonly found in the environment. It is also an opportunistic human pathogen known to cause a range of respiratory infections, such as invasive aspergillosis, particularly in immunocompromised individuals. Azole antifungal agents are widely used for the treatment and prophylaxis of Aspergillus infections due to their efficacy and tolerability. However, the emergence of azole resistance in A. fumigatus has become a major concern in recent years due to their association with increased treatment failures and mortality rates. The development of azole resistance in A. fumigatus can occur through both acquired and intrinsic mechanisms. Acquired resistance typically arises from mutations in the target enzyme, lanosterol 14-α-demethylase (Cyp51A), reduces the affinity of azole antifungal agents for the enzyme, rendering them less effective, while intrinsic resistance refers to a natural resistance of certain A. fumigatus isolates to azole antifungals due to inherent genetic characteristics. The current review aims to provide a comprehensive overview of azole antifungal resistance in A. fumigatus, discusses underlying resistance mechanisms, including alterations in the target enzyme, Cyp51A, and the involvement of efflux pumps in drug efflux. Impact of azole fungicide uses in the environment and the spread of resistant strains is also explored.
Identifiants
pubmed: 38878211
doi: 10.1007/s00203-024-04026-z
pii: 10.1007/s00203-024-04026-z
doi:
Substances chimiques
Azoles
0
Antifungal Agents
0
Fungal Proteins
0
cytochrome P-450 CYP51A, Aspergillus
EC 1.14.14.-
Cytochrome P-450 Enzyme System
9035-51-2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
305Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
(WHO), W. H. O (2022) WHO fungal priority pathogens list to guide research, development and public health action. W. H. O. (WHO), World Health Organization (WHO): 48
Aigner M, Lass-Florl C (2015) Treatment of drug-resistant aspergillus infection. Expert Opin Pharmacother 16(15):2267–2270
pubmed: 26328502
doi: 10.1517/14656566.2015.1083976
Alam S, Nisar M, Bano SA, Ahmad T (2022) Impact of aerial fungal spores on human health. Hazardous Environmental Micro-pollutants, Health Impacts and Allied Treatment Technologies, Springer: 219–240
Alcazar-Fuoli L, Mellado E (2014) Current status of antifungal resistance and its impact on clinical practice. Br J Haematol 166(4):471–484
pubmed: 24749533
doi: 10.1111/bjh.12896
Alqahtani MS, Kazi M (2021) Advances in oral drug delivery. Front Pharmacol 12:618411
pubmed: 33679401
pmcid: 7933596
doi: 10.3389/fphar.2021.618411
Amona FM, Oladele RO, Resendiz-Sharpe A, Denning DW, Kosmidis C, Lagrou K, Zhong H, Han L (2022) Triazole resistance in Aspergillus fumigatus isolates in Africa: a systematic review. Med Mycol 60(8)
Arastehfar A, Gabaldón T, Garcia-Rubio R, Jenks JD, Hoenigl M, Salzer HJ, Ilkit M, Lass-Flörl C, Perlin DS (2020) Drug-resistant fungi: an emerging challenge threatening our limited antifungal armamentarium. Antibiotics 9(12):877
pubmed: 33302565
pmcid: 7764418
doi: 10.3390/antibiotics9120877
Arastehfar A, Carvalho A, Houbraken J, Lombardi L, Garcia-Rubio R, Jenks JD, Rivero-Menendez O, Aljohani R, Jacobsen ID, Berman J, Osherov N, Hedayati MT, Ilkit M, Armstrong-James D, Gabaldon T, Meletiadis J, Kostrzewa M, Pan W, Lass-Florl C, Perlin DS, Hoenigl M (2021) Aspergillus Fumigatus and aspergillosis: from basics to clinics. Stud Mycol 100:100115
pubmed: 34035866
pmcid: 8131930
doi: 10.1016/j.simyco.2021.100115
Arendrup MC, Kahlmeter G, Guinea J, Meletiadis J, Testing S (2021) How to: perform antifungal susceptibility testing of microconidia-forming dermatophytes following the new reference EUCAST method E. Def 11.0, exemplified by Trichophyton. Clinical Microbiology and Infection 27(1): 55–60
Avkan-Oğuz V, Çelik M, Satoglu IS, Ergon MC (2020) and A. emrah Açan Primary cutaneous Aspergillosis in immunocompetent adults: three cases and a review of the literature. Cureus 12(1)
Baltussen TJH, Zoll J, Verweij PE, Melchers WJG (2020) Molecular mechanisms of Conidial Germination in Aspergillus spp. Microbiol Mol Biol Rev 84(1)
Bandres MV, Modi P, Sharma S (2023) Aspergillus Fumigatus. StatPearls. Treasure Island (FL)
Berkow EL, Lockhart SR, Ostrosky-Zeichner L (2020) Antifungal susceptibility testing: current approaches. Clin Microbiol Rev 33(3). https://doi.org/10.1128/cmr.00069-00019
Bermas A, Geddes-McAlister J (2020) Combatting the evolution of antifungal resistance in Cryptococcus neoformans. Mol Microbiol 114(5):721–734
pubmed: 32697029
doi: 10.1111/mmi.14565
Berna KY (2020) Imidazole antifungals: a review of their action mechanisms on cancerous cells. Int J Secondary Metabolite 7(3):139–159
doi: 10.21448/ijsm.714310
Bhattacharya S, Sae-Tia S, Fries BC (2020) Candidiasis Mech Antifungal Resist Antibiot (Basel) 9(6)
Bongomin F, Gago S, Oladele RO, Denning DW, (2017) J Fungi (Basel) 3(4)
Bosetti D, Neofytos D (2023) Invasive aspergillosis and the impact of azole-resistance. Curr Fungal Infect Rep 1–10
Bouz G, Dolezal M (2021) Advances in Antifungal Drug Development: an Up-To. -Date Mini Rev Pharmaceuticals (Basel) 14(12)
Burgess TB, Condliffe AM, Elks PM (2022) A fun-guide to innate immune responses to fungal infections. J Fungi 8(8):805
doi: 10.3390/jof8080805
Burks C, Darby A, Gomez Londono L, Momany M, Brewer MT (2021) Azole-resistant aspergillus fumigatus in the environment: identifying key reservoirs and hotspots of antifungal resistance. PLoS Pathog 17(7):e1009711
pubmed: 34324607
pmcid: 8321103
doi: 10.1371/journal.ppat.1009711
Burnham AJ, Magliocca KR, Pettitt-Schieber B, Edwards TS, Marcus S, DelGaudio JM, Wise SK, Levy JM, Roland LT (2022) Intermediate Invasive Fungal Sinusitis, a distinct entity from Acute Fulminant and Chronic Invasive Fungal Sinusitis. Annals of Otology. Rhinology Laryngology 131(9):1021–1026
doi: 10.1177/00034894211052854
Camps SM, van der Linden JW, Li Y, Kuijper EJ, van Dissel JT, Verweij PE, Melchers WJ (2012) Rapid induction of multiple resistance mechanisms in aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother 56(1):10–16
pubmed: 22005994
pmcid: 3256077
doi: 10.1128/AAC.05088-11
Carolus H, Pierson S, Lagrou K, Van Dijck P (2020) Amphotericin B and other Polyenes—Discovery, Clinical Use, Mode of Action and Drug Resistance. J Fungi 6(4):321
doi: 10.3390/jof6040321
Chen SC, Sorrell TC (2007) Antifungal agents. Med J Aust 187(7):404
pubmed: 17908006
doi: 10.5694/j.1326-5377.2007.tb01313.x
Chen P, Liu M, Zeng Q, Zhang Z, Liu W, Sang H, Lu L (2019) Uncovering new mutations conferring Azole Resistance in the aspergillus fumigatus cyp51A gene. Front Microbiol 10:3127
pubmed: 32038564
doi: 10.3389/fmicb.2019.03127
Chowdhary A, Sharma C, van den Boom M, Yntema JB, Hagen F, Verweij PE, Meis JF (2014) Multi-azole-resistant aspergillus fumigatus in the environment in Tanzania. J Antimicrob Chemother 69(11):2979–2983
pubmed: 25006238
doi: 10.1093/jac/dku259
Cipolletti M, Bartoloni S, Busonero C, Parente M, Leone S, Acconcia F (2021) A New Anti-estrogen Discovery platform identifies FDA-Approved imidazole anti-fungal drugs as Bioactive compounds against ERα. Expressing Breast Cancer Cells Int J Mol Sci 22(6):2915
pubmed: 33805656
Cowen LE, Lindquist S (2005) Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309(5744):2185–2189
pubmed: 16195452
doi: 10.1126/science.1118370
Cowen LE, Carpenter AE, Matangkasombut O, Fink GR, Lindquist S (2006) Genetic architecture of Hsp90-dependent drug resistance. Eukaryot Cell 5(12):2184–2188
pubmed: 17056742
pmcid: 1694807
doi: 10.1128/EC.00274-06
Cowen LE, Singh SD, Kohler JR, Collins C, Zaas AK, Schell WA, Aziz H, Mylonakis E, Perfect JR, Whitesell L, Lindquist S (2009) Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A 106(8):2818–2823
pubmed: 19196973
pmcid: 2650349
doi: 10.1073/pnas.0813394106
Cowen LE, Sanglard D, Howard SJ, Rogers PD, Perlin DS (2014) Mech Antifungal Drug Resist Cold Spring Harb Perspect Med 5(7):a019752
doi: 10.1101/cshperspect.a019752
Czyrski A, Resztak M, Swiderski P, Brylak J, Glowka FK (2021) Overv Pharmacokinetic Pharmacodynamic Interact Triazoles Pharm 13(11)
Denison HJ, Worswick J, Bond CM, Grimshaw JM, Mayhew A, Gnani Ramadoss S, Robertson C, Schaafsma ME, Watson MC (2020) Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev 8(8):CD002845
pubmed: 32845024
Denning DW, Morgan EF (2022) Quantifying deaths from aspergillosis in HIV positive people. J Fungi (Basel) 8(11)
Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, Manning NJ, Stevens DA, Warnock DW, Kelly SL (1997) Itraconazole resistance in aspergillus fumigatus. Antimicrob Agents Chemother 41(6):1364–1368
pubmed: 9174200
pmcid: 163916
doi: 10.1128/AAC.41.6.1364
Dhasarathan P, AlSalhi MS, Devanesan S, Subbiah J, Ranjitsingh A, Binsalah M, Alfuraydi AA (2021) Drug resistance in Candida albicans isolates and related changes in the structural domain of Mdr1 protein. J Infect Public Health 14(12):1848–1853
pubmed: 34794907
doi: 10.1016/j.jiph.2021.11.002
Douglas AP, Smibert OC, Bajel A, Halliday CL, Lavee O, McMullan B, Yong MK, van Hal SJ, Chen SCA and A. A. G. S. Committee (2021). Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021. Intern Med J 51: 143–176
Edson KK, Andrew N, Uwe G, Oliver B, Tohru G, Christine CB (2017) Diversity of Azoles Resistant Aspergillus Species Isolated from Experience and Naïve Soils in Nairobi County and Naivasha Sub-County Kenya. European Scientific Journal, ESJ 13(36)
Egbuta MA, Mwanza M, Babalola OO (2016) A review of the ubiquity of ascomycetes filamentous fungi in relation to their economic and medical importance. Adv Microbiol 6(14):1140–1158
doi: 10.4236/aim.2016.614103
Esquivel BD, White TC (2017) Accumulation of azole drugs in the fungal plant pathogen Magnaporthe Oryzae is the result of facilitated diffusion influx. Front Microbiol 8:275167
doi: 10.3389/fmicb.2017.01320
Esquivel BD, Smith AR, Zavrel M, White TC (2015) Azole drug import into the pathogenic fungus aspergillus fumigatus. Antimicrob Agents Chemother 59(6):3390–3398
pubmed: 25824209
pmcid: 4432157
doi: 10.1128/AAC.05003-14
Evans TJ, Lawal A, Kosmidis C, Denning DW (2023) Chronic pulmonary aspergillosis: clinical presentation and management. Seminars in respiratory and critical Care Medicine. Thieme Medical Publishers, Inc
Fisher MC, Alastruey-Izquierdo A, Berman J, Bicanic T, Bignell EM, Bowyer P, Bromley M, Bruggemann R, Garber G, Cornely OA, Gurr SJ, Harrison TS, Kuijper E, Rhodes J, Sheppard DC, Warris A, White PL, Xu J, Zwaan B, Verweij PE (2022) Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol 20(9):557–571
pubmed: 35352028
pmcid: 8962932
doi: 10.1038/s41579-022-00720-1
Fraczek MG, Bromley M, Buied A, Moore CB, Rajendran R, Rautemaa R, Ramage G, Denning DW, Bowyer P (2013) The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in aspergillus fumigatus. J Antimicrob Chemother 68(7):1486–1496
pubmed: 23580559
doi: 10.1093/jac/dkt075
Frisvad JC, Larsen TO (2015) Extrolites of aspergillus fumigatus and other pathogenic species in Aspergillus Section Fumigati. Front Microbiol 6:1485
pubmed: 26779142
Ghannoum MA, Rice LB (1999) Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12(4):501–517
pubmed: 10515900
pmcid: 88922
doi: 10.1128/CMR.12.4.501
Giichiro O, Shinji O, Atsushi I (2018) Human Beings in Antarctica. Antarctica. K. Masaki, T. Genti and Y. Masa-yuki. Rijeka, IntechOpen: Ch. 8
Giske CG, Turnidge J, Cantón R, Kahlmeter G (2022) Update from the European committee on antimicrobial susceptibility testing (EUCAST). J Clin Microbiol 60(3):e00276–e00221
pubmed: 34346716
pmcid: 8925892
doi: 10.1128/jcm.00276-21
Goldberg I, Rokem JS, Pines O (2006) Organic acids: old metabolites, new themes. J Chem Technol Biotechnol 81(10):1601–1611
doi: 10.1002/jctb.1590
Gomez M, Campusano S, Gutierrez MS, Sepulveda D, Barahona S, Baeza M, Cifuentes V, Alcaino J (2020) Sterol regulatory element-binding protein Sre1 regulates carotenogenesis in the red yeast Xanthophyllomyces Dendrorhous. J Lipid Res 61(12):1658–1674
pubmed: 32933952
pmcid: 7707178
doi: 10.1194/jlr.RA120000975
Gomez Londono LF, Brewer MT (2023) Detection of azole-resistant aspergillus fumigatus in the environment from air, plant debris, compost, and soil. PLoS ONE 18(3):e0282499
pubmed: 36867648
pmcid: 9983824
doi: 10.1371/journal.pone.0282499
Gonzalez-Jimenez I, Garcia-Rubio R, Monzon S, Lucio J, Cuesta I, Mellado E (2021) Multiresistance to Nonazole fungicides in Aspergillus Fumigatus TR(34)/L98H azole-resistant isolates. Antimicrob Agents Chemother 65(9):e0064221
pubmed: 34152819
doi: 10.1128/AAC.00642-21
Gow NAR, Johnson C, Berman J, Coste AT, Cuomo CA, Perlin DS, Bicanic T, Harrison TS, Wiederhold N, Bromley M, Chiller T, Edgar K (2022) The importance of antimicrobial resistance in medical mycology. Nat Commun 13(1):5352
pubmed: 36097014
pmcid: 9466305
doi: 10.1038/s41467-022-32249-5
Hammoudi Halat D, Younes S, Mourad N, Rahal M (2022) Allylamines, Benzylamines, and fungal cell permeability: a review of mechanistic effects and usefulness against fungal pathogens. Membr (Basel) 12(12)
Hoenigl M, Arastehfar A, Arendrup MC, Brüggemann R, Carvalho A, Chiller T, Chen S, Egger M, Feys S, Gangneux J-P (2024) Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease. Clin Microbiol Rev e00074–e00023
Hossain CM, Ryan LK, Gera M, Choudhuri S, Lyle N, Ali KA, Diamond G (2022) Antifungals drug Resist Encyclopedia 2(4):1722–1737
Howard SJ, Webster I, Moore CB, Gardiner RE, Park S, Perlin DS, Denning DW (2006) Multi-azole resistance in aspergillus fumigatus. Int J Antimicrob Agents 28(5):450–453
pubmed: 17034993
doi: 10.1016/j.ijantimicag.2006.08.017
Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, Laverdiere M, Arendrup MC, Perlin DS, Denning DW (2009) Frequency and evolution of azole resistance in aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 15(7):1068–1076
pubmed: 19624922
pmcid: 2744247
doi: 10.3201/eid1507.090043
Hsu TH, Huang PY, Fan YC, Sun PL (2022) Azole Resistance and cyp51A Mutation of Aspergillus Fumigatus in a Tertiary Referral Hospital in Taiwan. J Fungi (Basel) 8(9)
Ijadpanahsaravi M, Teertstra WR, Wosten HAB (2022) Inter- and intra-species heterogeneity in germination of aspergillus conidia. Antonie Van Leeuwenhoek 115(9):1151–1164
pubmed: 35857156
pmcid: 9363317
doi: 10.1007/s10482-022-01762-4
Imai J, Yahara I (2000) Role of HSP90 in salt stress tolerance via stabilization and regulation of calcineurin. Mol Cell Biol 20(24):9262–9270
pubmed: 11094077
pmcid: 102183
doi: 10.1128/MCB.20.24.9262-9270.2000
Kang SE, Sumabat LG, Melie T, Mangum B, Momany M, Brewer MT (2022) Evidence for the agricultural origin of resistance to multiple antimicrobials in aspergillus fumigatus, a fungal pathogen of humans. G3 (Bethesda) 12(2)
Karaffa L, Kubicek CP (2003) Aspergillus Niger citric acid accumulation: do we understand this well working black box? Appl Microbiol Biotechnol 61:189–196
pubmed: 12698275
doi: 10.1007/s00253-002-1201-7
Kemoi EK, Nyerere A, Bii CC (2018) Triazole-Resistant Aspergillus fumigatus from Fungicide-Experienced Soils in Naivasha Subcounty and Nairobi County, Kenya. Int J Microbiol 2018: 7147938
Kharb R, Sharma PC, Yar MS (2011) Pharmacological significance of triazole scaffold. J Enzyme Inhib Med Chem 26(1):1–21
pubmed: 20583859
doi: 10.3109/14756360903524304
Korashy HM, Shayeganpour A, Brocks DR, El-Kadi AO (2007) Induction of cytochrome P450 1A1 by ketoconazole and itraconazole but not fluconazole in murine and human hepatoma cell lines. Toxicol Sci 97(1):32–43
pubmed: 17283379
doi: 10.1093/toxsci/kfm012
Krishnan Natesan S, Wu W, Cutright JL, Chandrasekar PH (2012) In vitro-in vivo correlation of voriconazole resistance due to G448S mutation (cyp51A gene) in aspergillus fumigatus. Diagn Microbiol Infect Dis 74(3):272–277
pubmed: 22897872
doi: 10.1016/j.diagmicrobio.2012.06.030
Kuhbacher A, Peiffer M, Hortschansky P, Merschak P, Bromley MJ, Haas H, Brakhage AA, Gsaller F (2022) Azole Resistance-Associated Regulatory Motifs within the promoter of cyp51A in aspergillus fumigatus. Microbiol Spectr 10(3):e0120922
pubmed: 35575535
doi: 10.1128/spectrum.01209-22
Lai CC, Yu WL (2021) COVID-19 associated with pulmonary aspergillosis: a literature review. J Microbiol Immunol Infect 54(1):46–53
pubmed: 33012653
doi: 10.1016/j.jmii.2020.09.004
Lakhani P, Patil A, Majumdar S (2019) Challenges in the polyene- and azole-based pharmacotherapy of ocular fungal infections. J Ocul Pharmacol Ther 35(1):6–22
pubmed: 30481082
pmcid: 6354613
doi: 10.1089/jop.2018.0089
Lamoth F, Juvvadi PR, Gehrke C, Asfaw YG, Steinbach WJ (2014) Transcriptional activation of heat shock protein 90 mediated via a proximal promoter region as trigger of caspofungin resistance in aspergillus fumigatus. J Infect Dis 209(3):473–481
pubmed: 24096332
doi: 10.1093/infdis/jit530
Langfeldt A, Gold JAW, Chiller T (2022) Emerging fungal infections: from the fields to the clinic, resistant aspergillus fumigatus and dermatophyte species: a one health perspective on an Urgent Public Health Problem. Curr Clin Microbiol Rep 9(4):46–51
pubmed: 36188157
pmcid: 9512973
doi: 10.1007/s40588-022-00181-3
Lepesheva I, G. and, Waterman MR (2011) Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis. Curr Top Med Chem 11(16):2060–2071
pubmed: 21619513
pmcid: 3391166
doi: 10.2174/156802611796575902
Lestrade PPA, Meis JF, Melchers WJG, Verweij PE (2019) Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management. Clin Microbiol Infect 25(7):799–806
pubmed: 30580035
doi: 10.1016/j.cmi.2018.11.027
Looi CY, D’ Silva EC, Seow HF, Rosli R, Ng KP, Chong PP (2005) Increased expression and hotspot mutations of the multidrug efflux transporter, CDR1 in azole-resistant Candida albicans isolates from vaginitis patients. FEMS Microbiol Lett 249(2):283–289
pubmed: 16006060
doi: 10.1016/j.femsle.2005.06.036
López-Gamboa JA, Toledo-Bahena ME, Bonifaz A, Valencia-Herrera A, Camargo-Sánchez KA, Duarte-Abdala M, Mena-Cedillos CA (2021) Cutaneous aspergillosis in children and adolescents. Curr Fungal Infect Rep 15(2):41–48
doi: 10.1007/s12281-021-00410-0
Lupianez CB, Martinez-Bueno M, Sanchez-Maldonado JM, Badiola J, Cunha C, Springer J, Lackner M, Segura-Catena J, Canet LM, Alcazar-Fuoli L, Lopez-Nevot MA, Fianchi L, Aguado JM, Pagano L, Lopez-Fernandez E, Alarcon-Riquelme M, Potenza L, Goncalves SM, Luppi M, Moratalla L, Solano C, Sampedro A, Gonzalez-Sierra P, Cuenca-Estrella M, Lagrou K, Maertens JA, Lass-Florl C, Einsele H, Vazquez L, Group PS, Loeffler J, Rios-Tamayo R, Carvalho A, Jurado M, Sainz J (2020) Polymorphisms within the ARNT2 and CX3CR1 genes are Associated with the risk of developing invasive aspergillosis. Infect Immun 88(4).
Mann PA, Parmegiani RM, Wei SQ, Mendrick CA, Li X, Loebenberg D, DiDomenico B, Hare RS, Walker SS, McNicholas PM (2003) Mutations in aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Antimicrob Agents Chemother 47(2):577–581
pubmed: 12543662
pmcid: 151774
doi: 10.1128/AAC.47.2.577-581.2003
Mansfield BE, Oltean HN, Oliver BG, Hoot SJ, Leyde SE, Hedstrom L, White TC (2010) Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi. PLoS Pathog 6(9):e1001126
pubmed: 20941354
pmcid: 2947996
doi: 10.1371/journal.ppat.1001126
Marek CL, Timmons SR (2019) 9 - Antimicrobials in Pediatric Dentistry. Pediatric Dentistry (Sixth Edition). A. J. Nowak, J. R. Christensen, T. R. Mabry, J. A. Townsend and M. H. Wells. Philadelphia, Elsevier: 128–141.e121
Marta W, Beata S-T, Wojciech F, Grzegorz N, Krzysztof Z (2019) Invasive Aspergillosis in Transplant Recipients. Surgical Recovery. S. Selim. Rijeka, IntechOpen: Ch. 6
Mast N, Zheng W, Stout CD, Pikuleva IA (2013) Antifungal azoles: structural insights into undesired tight binding to cholesterol-metabolizing CYP46A1. Mol Pharmacol 84(1):86–94
pubmed: 23604141
pmcid: 3684827
doi: 10.1124/mol.113.085902
Matin MM, Matin P, Rahman MR, Ben Hadda T, Almalki FA, Mahmud S, Ghoneim MM, Alruwaily M, Alshehri S (2022) Triazoles and their derivatives: Chemistry, Synthesis, and therapeutic applications. Front Mol Biosci 9:864286
pubmed: 35547394
pmcid: 9081720
doi: 10.3389/fmolb.2022.864286
Mazu K, Bricker TBA, Flores-Rozas H, Ablordeppey SY (2016) The mechanistic targets of antifungal agents: an overview. Mini Rev Med Chem 16(7):555–578
pubmed: 26776224
pmcid: 5215921
doi: 10.2174/1389557516666160118112103
McCormick A, Loeffler J, Ebel F (2010) Aspergillus Fumigatus: contours of an opportunistic human pathogen. Cell Microbiol 12(11):1535–1543
pubmed: 20716206
doi: 10.1111/j.1462-5822.2010.01517.x
Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Melchers WJ, Verweij PE, Cuenca-Estrella M, Rodriguez-Tudela JL (2007) A new aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 51(6):1897–1904
pubmed: 17371828
pmcid: 1891382
doi: 10.1128/AAC.01092-06
Moore C, Sayers N, Mosquera J, Slaven J, Denning D (2000) Antifungal drug resistance in Aspergillus. J Infect 41(3):203–220
pubmed: 11120607
doi: 10.1053/jinf.2000.0747
Morogovsky A, Handelman M, Abou Kandil A, Shadkchan Y, Osherov N (2022) Horizontal Gene Transfer of Triazole Resistance in Aspergillus Fumigatus. Microbiol Spectr 10(3):e0111222
pubmed: 35652640
doi: 10.1128/spectrum.01112-22
Mousset S, Buchheidt D, Heinz W, Ruhnke M, Cornely OA, Egerer G, Kruger W, Link H, Neumann S, Ostermann H, Panse J, Penack O, Rieger C, Schmidt-Hieber M, Silling G, Sudhoff T, Ullmann AJ, Wolf HH, Maschmeyer G, Bohme A (2014) Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 93(1):13–32
pubmed: 24026426
doi: 10.1007/s00277-013-1867-1
Moye-Rowley WS (2020) Linkage between genes involved in azole resistance and ergosterol biosynthesis. PLoS Pathog 16(9):e1008819
pubmed: 32881974
pmcid: 7470339
doi: 10.1371/journal.ppat.1008819
Mroczyńska M, Brillowska-Dąbrowska A (2020) Rev Curr Status Echinocandins Use Antibiot (Basel) 9(5)
Mushi MF, Buname G, Bader O, Gross U, Mshana SE (2016) Aspergillus Fumigatus carrying TR34/L98H resistance allele causing complicated suppurative otitis media in Tanzania: call for improved diagnosis of fungi in sub-saharan Africa. BMC Infect Dis 16(1):464
pubmed: 27589956
pmcid: 5009654
doi: 10.1186/s12879-016-1796-4
Nywening AV, Rybak JM, Rogers PD, Fortwendel JR (2020) Mechanisms of triazole resistance in aspergillus fumigatus. Environ Microbiol 22(12):4934–4952
pubmed: 33047482
pmcid: 7828461
doi: 10.1111/1462-2920.15274
Oliveira FFM, Paes HC, Peconick LDF, Fonseca FL, Marina CLF, Bocca AL, Homem-de-Mello M, Rodrigues ML, Albuquerque P, Nicola AM (2020) Erg6 affects membrane composition and virulence of the human fungal pathogen Cryptococcus neoformans. Fungal Genet Biol 140:103368
pubmed: 32201128
pmcid: 7293587
doi: 10.1016/j.fgb.2020.103368
Otu A, Osaigbovo I, Orefuwa E, Ebenso B, Ojumu T (2021) Collaborative One Health approaches can mitigate increasing azole-resistant aspergillus fumigatus in Africa. Lancet Microbe 2(10):e490–e491
pubmed: 35544173
doi: 10.1016/S2666-5247(21)00218-4
Pariza MW, Cook M (2010) Determining the safety of enzymes used in animal feed. Regul Toxicol Pharmacol 56(3):332–342
pubmed: 19879914
doi: 10.1016/j.yrtph.2009.10.005
Park N-H, Shin K-H, Kang MK 34 - Antifungal and Antiviral Agents. Pharmacology and Therapeutics for Dentistry (Seventh Edition)., Dowd FJ, Johnson BS, Mariotti AJ (2017) Mosby: 488–503
Parker JE, Merkamm M, Manning NJ, Pompon D, Kelly SL, Kelly DE (2008) Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus. Antimicrob Agents Chemother 52(10):3597–3603
pubmed: 18694951
pmcid: 2565906
doi: 10.1128/AAC.00517-08
Parmar BD, Jha SG, Sinha V, Chaudhari NP, Dave GP (2020) A prospective analytic study of invasive fungal rhinosinsitis. Int J Otorhinolaryngol Head Neck Surg 6(4):652
doi: 10.18203/issn.2454-5929.ijohns20201294
Paul S, Stamnes M, Thomas GH, Liu H, Hagiwara D, Gomi K, Filler SG, Moye-Rowley WS (2019) AtrR is an essential determinant of Azole Resistance in Aspergillus Fumigatus. mBio 10(2)
Perez-Cantero A, Lopez-Fernandez L, Guarro J, Capilla J (2020) Azole resistance mechanisms in aspergillus: update and recent advances. Int J Antimicrob Agents 55(1):105807
pubmed: 31542320
doi: 10.1016/j.ijantimicag.2019.09.011
Perez-Rivera AA, Hu T, Aardema MJ, Nash JF (2009) Evaluation of the genotoxicity of the imidazole antifungal climbazole: comparison to published results for other azole compounds. Mutat Res 672(1):27–39
pubmed: 18950734
doi: 10.1016/j.mrgentox.2008.09.011
Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A (2017) The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis 17(12):e383–e392
pubmed: 28774698
doi: 10.1016/S1473-3099(17)30316-X
Peyton LR, Gallagher S, Hashemzadeh M (2015) Triazole antifungals: a review. Drugs Today (Barc) 51(12):705–718
pubmed: 26798851
doi: 10.1358/dot.2015.51.12.2421058
Pogue JM, Jones RN, Bradley JS, Andes DR, Bhavnani SM, Drusano GL, Dudley MN, Flamm RK, Rodvold KA, Ambrose PG (2020) Polymyxin susceptibility testing and interpretive breakpoints: recommendations from the United States Committee on Antimicrobial susceptibility testing (USCAST). Antimicrob Agents Chemother 64(2). https://doi.org/10.1128/aac01495-01419
Resendiz Sharpe A, Lagrou K, Meis JF, Chowdhary A, Lockhart SR P. E. Verweij and I. E. A. R. S. w. group (2018). Triazole resistance surveillance in aspergillus fumigatus. Med Mycol 56(suppl_1): 83–92
Resendiz-Sharpe A, Dewaele K, Merckx R, Bustamante B, Vega-Gomez MC, Rolon M, Jacobs J, Verweij PE, Maertens J, Lagrou K (2021) Triazole-resistance in Environmental Aspergillus Fumigatus in Latin American and African Countries. J Fungi (Basel) 7(4)
Rhodes J, Abdolrasouli A, Dunne K, Sewell TR, Zhang Y, Ballard E, Brackin AP, van Rhijn N, Chown H, Tsitsopoulou A, Posso RB, Chotirmall SH, McElvaney NG, Murphy PG, Talento AF, Renwick J, Dyer PS, Szekely A, Bowyer P, Bromley MJ, Johnson EM, Lewis White P, Warris A, Barton RC, Schelenz S, Rogers TR, Armstrong-James D, Fisher MC (2022) Population genomics confirms acquisition of drug-resistant aspergillus fumigatus infection by humans from the environment. Nat Microbiol 7(5):663–674
pubmed: 35469019
pmcid: 9064804
doi: 10.1038/s41564-022-01091-2
Risum M, Hare RK, Gertsen JB, Kristensen L, Rosenvinge FS, Sulim S, Abou-Chakra N, Bangsborg J, Roder BL, Marmolin ES, Astvad KMT, Pedersen M, Dzajic E, Andersen SL, Arendrup MC (2022) Azole resistance in aspergillus fumigatus. The first 2-year’s data from the Danish National Surveillance Study, 2018–2020. Mycoses 65(4):419–428
pubmed: 35104010
pmcid: 9302650
doi: 10.1111/myc.13426
Rivero-Menendez O, Alastruey-Izquierdo A, Mellado E, Cuenca-Estrella M (2016) Triazole Resistance in Aspergillus spp.: a Worldwide Problem? J Fungi (Basel) 2(3)
Rogers TR, Verweij PE, Castanheira M, Dannaoui E, White PL, Arendrup MC (2022) Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications. J Antimicrob Chemother 77(8):2053–2073
pubmed: 35703391
pmcid: 9333407
doi: 10.1093/jac/dkac161
Rosam K, Monk BC, Lackner M (2020) Sterol 14α-demethylase ligand-binding pocket-mediated acquired and intrinsic azole resistance in fungal pathogens. J Fungi 7(1):1
doi: 10.3390/jof7010001
Sanderson JT (2006) The steroid hormone biosynthesis pathway as a target for endocrine-disrupting chemicals. Toxicol Sci 94(1):3–21
pubmed: 16807284
doi: 10.1093/toxsci/kfl051
Schelenz S, Owens K, Guy R, Rautemaa-Richardson R, Manuel RJ, Richardson M, Moore C, Enoch DA, Micallef C, Howard P, Agrawal SG, Johnson EM, Muller-Pebody B (2019) National Mycology laboratory diagnostic capacity for invasive fungal diseases in 2017: evidence of sub-optimal practice. J Infect 79(2):167–173
pubmed: 31233810
doi: 10.1016/j.jinf.2019.06.009
Sen P, Vijay M, Singh S, Hameed S, Vijayaraghavan P (2022) Understanding the environmental drivers of clinical azole resistance in aspergillus species. Drug Target Insights 16:25–35
pubmed: 36458152
pmcid: 9685629
doi: 10.33393/dti.2022.2476
Shafiei M, Peyton L, Hashemzadeh M, Foroumadi A (2020) History of the development of antifungal azoles: a review on structures, SAR, and mechanism of action. Bioorg Chem 104:104240
pubmed: 32906036
doi: 10.1016/j.bioorg.2020.104240
Sharma C, Hagen F, Moroti R, Meis JF, Chowdhary A (2015) Triazole-resistant aspergillus fumigatus harbouring G54 mutation: is it de novo or environmentally acquired? J Glob Antimicrob Resist 3(2):69–74
pubmed: 27873672
doi: 10.1016/j.jgar.2015.01.005
Sheehan DJ, Hitchcock CA, Sibley CM (1999) Current and emerging azole antifungal agents. Clin Microbiol Rev 12(1):40–79
pubmed: 9880474
pmcid: 88906
doi: 10.1128/CMR.12.1.40
Shetty S, Chandrashekar S, Aggarwal N (2020) A study on the prevalence and clinical features of fungal sinusitis in chronic rhinosinusitis. Indian J Otolaryngol Head Neck Surg 72(1):117–122
pubmed: 32158667
doi: 10.1007/s12070-019-01769-w
Singh SD, Robbins N, Zaas AK, Schell WA, Perfect JR, Cowen LE (2009) Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog 5(7):e1000532
pubmed: 19649312
pmcid: 2712069
doi: 10.1371/journal.ppat.1000532
Snelders E, ‘t Huis RA (2009) Veld, A. J. Rijs, G. H. Kema, W. J. Melchers and P. E. Verweij Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol 75(12): 4053–4057
Snelders E, Karawajczyk A, Schaftenaar G, Verweij PE, Melchers WJ (2010) Azole resistance profile of amino acid changes in aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob Agents Chemother 54(6):2425–2430
pubmed: 20385860
pmcid: 2876375
doi: 10.1128/AAC.01599-09
Sruthi M (2021) How_do_echinocandin_antifungals_work. B. Sarfaroj Khan. PGD Health Operations
Sunman B, Ademhan Tural D, Ozsezen B, Emiralioglu N, Yalcin E, Özçelik U (2020) Current approach in the diagnosis and management of allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Front Pead 8:582964
doi: 10.3389/fped.2020.582964
Szymanski M, Chmielewska S, Czyzewska U, Malinowska M, Tylicki A (2022) Echinocandins - structure, mechanism of action and use in antifungal therapy. J Enzyme Inhib Med Chem 37(1):876–894
pubmed: 35296203
pmcid: 8933026
doi: 10.1080/14756366.2022.2050224
Taxvig C, Vinggaard AM, Hass U, Axelstad M, Metzdorff S, Nellemann C (2008) Endocrine-disrupting properties in vivo of widely used azole fungicides. Int J Androl 31(2):170–177
pubmed: 18067565
doi: 10.1111/j.1365-2605.2007.00838.x
Teixeira MM, Carvalho DT, Sousa E, Pinto E (2022) ew Antifungal Agents with Azole Moieties. Pharmaceuticals
Tseng H-K, Perfect JR (2011) Strategies to manage antifungal drug resistance. Expert Opin Pharmacother 12(2):241–256
pubmed: 21226635
doi: 10.1517/14656566.2010.517195
van der Torre MH, Novak-Frazer L, Rautemaa-Richardson R, (2020) J Fungi (Basel) 6(1)
Van Rhijn N, Bromley M (2021) The consequences of our changing environment on life threatening and debilitating fungal diseases in humans. J Fungi 7(5):367
doi: 10.3390/jof7050367
Verweij PE, Arendrup MC, Alastruey-Izquierdo A, Gold JAW, Lockhart SR, Chiller T, White PL (2022) Dual use of antifungals in medicine and agriculture: how do we help prevent resistance developing in human pathogens? Drug Resist Updat 65:100885
pubmed: 36283187
pmcid: 10693676
doi: 10.1016/j.drup.2022.100885
Visagie CM, Houbraken J (2020) Updating the taxonomy of aspergillus in South Africa. Stud Mycol 95(1):253–292
pubmed: 32855741
pmcid: 7426233
doi: 10.1016/j.simyco.2020.02.003
Vishwakarma M, Haider T, Soni V (2024) Update on fungal lipid biosynthesis inhibitors as antifungal agents. Microbiol Res 278:127517
pubmed: 37863019
doi: 10.1016/j.micres.2023.127517
Wadhwa HKR (2023) Itraconazole. StatPearls [Internet]. Treasure Island (FL), StatPearls Publishing
Warrilow AG, Parker JE, Kelly DE, Kelly SL (2013) Azole affinity of sterol 14alpha-demethylase (CYP51) enzymes from Candida albicans and Homo sapiens. Antimicrob Agents Chemother 57(3):1352–1360
pubmed: 23274672
pmcid: 3591892
doi: 10.1128/AAC.02067-12
Watt K, Manzoni P, Cohen-Wolkowiez M, Rizzollo S, Boano E, Jacqz-Aigrain E, Benjamin DK (2013) Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole. Curr Drug Metab 14(2):193–202
pubmed: 22935068
pmcid: 3541435
Wei X, Zhang Y, Lu L (2015) The molecular mechanism of azole resistance in Aspergillus fumigatus: from bedside to bench and back. J Microbiol 53(2):91–99
pubmed: 25626363
doi: 10.1007/s12275-015-5014-7
Wiederhold NP, Verweij PE (2020) Aspergillus Fumigatus and pan-azole resistance: who should be concerned? Curr Opin Infect Dis 33(4):290–297
pubmed: 32657965
doi: 10.1097/QCO.0000000000000662
Xiong Q, Hassan SA, Wilson WK, Han XY, May GS, Tarrand JJ, Matsuda SP (2005) Cholesterol import by aspergillus fumigatus and its influence on antifungal potency of sterol biosynthesis inhibitors. Antimicrob Agents Chemother 49(2):518–524
pubmed: 15673727
pmcid: 547240
doi: 10.1128/AAC.49.2.518-524.2005
Yardimci BK (2020) Imidazole antifungals: a review of their action mechanisms on cancerous cells. Int J Secondary Metabolite 7(3):139–159
doi: 10.21448/ijsm.714310
Yerbanga IW, Resendiz-Sharpe A, Bamba S, Lagrou K, Nakanabo Diallo S, Rodriguez-Villalobos H, Denis O, Montesinos I (2021) First investigative study of azole-resistant aspergillus fumigatus in the Environment in Burkina Faso. Int J Environ Res Public Health 18(5)
Yuan R, Tu J, Sheng C, Chen X, Liu N (2021) Effects of Hsp90 inhibitor ganetespib on inhibition of Azole-Resistant Candida albicans. Front Microbiol 12:680382
pubmed: 34093502
pmcid: 8174564
doi: 10.3389/fmicb.2021.680382
Zhang R, Zhang Y, Xu W, Han X, Zhao J (2023) Primary cutaneous aspergillosis due to aspergillus fumigatus in an Immunocompetent patient with diabetes Mellitus after Tattooing: a Case Report and Review of Literature. Infect Drug Resist 16:791–797
pubmed: 36779045
pmcid: 9911907
doi: 10.2147/IDR.S398858